Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 1997

View Archived Issues

Company Profile: Sibia Neurosciences

Bristol-Myers Squibb announces plans to double new product launches, overviews pipeline

Scherer, Elan extend Zydis selegiline licensing agreement

Cytel initiates registration trials of Cylexin in newborns

Apligraf scheduled for FDA advisory panel review

Procter & Gamble's COX-2 inhibitor in preclinical testing

RD4-6250: a potential new treatment for HCV

HNE inhibitors prepared at Glaxo Wellcome

Tanabe Seiyaku claims new PAI-1 inhibitors

Jouveinal patents PDE IV inhibitors

Peptidomimetic protein farnesyltransferase inhibitors in development at Merck

New antibacterial agent discovered by Sankyo

ACAT and lipid peroxidation inhibitors prepared at Tanabe Seiyaku

CCK-A antagonists revealed by Tobishi

Mitsui presents new antipsychotic agent

New AVP(4-9) analogue with beneficial effects on cognitive/memory deficits

Bayer/Genzyme drug discovery collaboration

Boehringer Ingelheim to develop and market Procysteine in Japan

Teijin starts clinical trials of in-licensed antiasthmatic drug

Neurogen updates its NPY program for obesity

BLA filed for palivizumab

Enzo's HIV gene therapy nears clinical testing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...